Liquid Biopsy in Hepatocellular Carcinoma

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Biomarkers in Cancer Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-981-13-7295-7_8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy for hepatocellular carcinoma: current status and future perspectives

  2018cited by this paper
• Detection and localization of surgically resectable cancers with a multi-analyte blood test

  2018cited by this paper
• MicroRNAs in Autoimmunity and Hematological Malignancies

  2018cited by this paper
• Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.

  2018cited by this paper
• Liquid biopsies for hepatocellular carcinoma

  2018cited by this paper
• Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics

  2018cited by this paper
• Epigenetics and MicroRNAs in Cancer

  2018cited by this paper
• Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook

  2018cited by this paper
• Circulating tumor DNA detection in hepatocellular carcinoma.

  2018cited by this paper
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

  2018cited by this paper
• Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids

  2017cited by this paper
• Circulating tumor DNA profiling reveals clonal evolution and real‐time disease progression in advanced hepatocellular carcinoma

  2017cited by this paper
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

  2017cited by this paper
• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

  2017cited by this paper
• Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations

  2017cited by this paper
• Breast cancer: The translation of big genomic data to cancer precision medicine

  2017cited by this paper
• The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma

  2017cited by this paper
• Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.

  2017cited by this paper
• MicroRNAs and clinical implications in hepatocellular carcinoma

  2017cited by this paper
• Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers

  2016cited by this paper
• Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

  2016cited by this paper
• A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.

  2015cited by this paper
• miRNA in hepatocellular carcinoma

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

  2015cited by this paper
• Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

  2014cited by this paper
• Liquid biopsies: genotyping circulating tumor DNA.

  2014cited by this paper
• c‐Myc‐mediated epigenetic silencing of MicroRNA‐101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma

  2014cited by this paper
• Hepatocellular carcinoma: clinical frontiers and perspectives

  2014cited by this paper
• Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies

  2014cited by this paper
• FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

  2013cited by this paper
• Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma

  2011cited by this paper
• Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.

  2011cited by this paper
• Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma.

  2010cited by this paper
• Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer

  2009cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  2004cited by this paper
• The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

  2003cited by this paper
• [Hepatocellular carcinoma].

  1988cited by this paper

• Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma

  2024cites this paper
• Liquid Biopsy in Hepatocellular Carcinoma: The Significance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Monitoring

  2023cites this paper
• Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review

  2023cites this paper
• Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma

  2022cites this paper
• Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice

  2022cites this paper
• Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma

  2022cites this paper
• Integration of transcriptomes analysis with spectral signature of total RNA for generation of affordable remote sensing of Hepatocellular carcinoma in serum clinical specimens

  2021cites this paper